Collegium Pharmaceutical ... (COLL)
Collegium Pharmaceutical Statistics
Share Statistics
Collegium Pharmaceutical has 31.49M shares outstanding. The number of shares has increased by 0.91% in one year.
| Shares Outstanding | 31.49M |
| Shares Change (YoY) | 0.91% |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 30.26M |
| Failed to Deliver (FTD) Shares | 347 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 5.62M, so 17.41% of the outstanding shares have been sold short.
| Short Interest | 5.62M |
| Short % of Shares Out | 17.41% |
| Short % of Float | 18.04% |
| Short Ratio (days to cover) | 11.21 |
Valuation Ratios
The PE ratio is 13.36 and the forward PE ratio is 4.94. Collegium Pharmaceutical's PEG ratio is 0.4.
| PE Ratio | 13.36 |
| Forward PE | 4.94 |
| PS Ratio | 1.46 |
| Forward PS | 1.3 |
| PB Ratio | 4.04 |
| P/FCF Ratio | 4.55 |
| PEG Ratio | 0.4 |
Enterprise Valuation
Collegium Pharmaceutical Inc. has an Enterprise Value (EV) of 1.71B.
| EV / Earnings | 24.76 |
| EV / Sales | 2.71 |
| EV / EBITDA | 10.08 |
| EV / EBIT | 10.08 |
| EV / FCF | 8.42 |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 3.75.
| Current Ratio | 0.95 |
| Quick Ratio | 0.88 |
| Debt / Equity | 3.75 |
| Total Debt / Capitalization | 78.97 |
| Cash Flow / Debt | 0.24 |
| Interest Coverage | 2.3 |
Financial Efficiency
Return on equity (ROE) is 0.3% and return on capital (ROIC) is 10.96%.
| Return on Equity (ROE) | 0.3% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 10.96% |
| Revenue Per Employee | $1,768,764.71 |
| Profits Per Employee | $193,809.52 |
| Employee Count | 357 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 7.15 |
Taxes
| Income Tax | 29.38M |
| Effective Tax Rate | 0.3 |
Stock Price Statistics
The stock price has increased by -23.91% in the last 52 weeks. The beta is 0.99, so Collegium Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -23.91% |
| 50-Day Moving Average | 30.5 |
| 200-Day Moving Average | 33.11 |
| Relative Strength Index (RSI) | 47.41 |
| Average Volume (20 Days) | 420.39K |
Income Statement
In the last 12 months, Collegium Pharmaceutical had revenue of 631.45M and earned 69.19M in profits. Earnings per share was 2.14.
| Revenue | 631.45M |
| Gross Profit | 377.34M |
| Operating Income | 169.9M |
| Net Income | 69.19M |
| EBITDA | 169.9M |
| EBIT | 169.9M |
| Earnings Per Share (EPS) | 2.14 |
Balance Sheet
The company has 70.56M in cash and 859.3M in debt, giving a net cash position of -788.73M.
| Cash & Cash Equivalents | 70.56M |
| Total Debt | 859.3M |
| Net Cash | -788.73M |
| Retained Earnings | -164M |
| Total Assets | 1.66B |
| Working Capital | 416.86M |
Cash Flow
In the last 12 months, operating cash flow was 204.98M and capital expenditures -1.65M, giving a free cash flow of 203.33M.
| Operating Cash Flow | 204.98M |
| Capital Expenditures | -1.65M |
| Free Cash Flow | 203.33M |
| FCF Per Share | 6.3 |
Margins
Gross margin is 59.76%, with operating and profit margins of 26.91% and 10.96%.
| Gross Margin | 59.76% |
| Operating Margin | 26.91% |
| Pretax Margin | 15.61% |
| Profit Margin | 10.96% |
| EBITDA Margin | 26.91% |
| EBIT Margin | 26.91% |
| FCF Margin | 32.2% |
Dividends & Yields
COLL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.24% |
| FCF Yield | 21.86% |
Analyst Forecast
The average price target for COLL is $44, which is 49% higher than the current price. The consensus rating is "Buy".
| Price Target | $44 |
| Price Target Difference | 49% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 3.32 |
| Piotroski F-Score | 7 |